Our SPOTLIGHT COMPANY


Oragenics, Inc. (NYSE American: OGEN)
Oragenics, Inc. represents a compelling investment opportunity with its forwardthinking leadership and cutting edge technology.  Oragenics is set to make waves in the market. Oragenics recently expanded its portfolio to encompass neurological drug therapies and technologies via the acquisition and partnership with Odyssey Health, Inc.

This strategic move positions Oragenics at the forefront of healthcare innovation, making it an attractive prospect for healthcare investors. Oragenics is also emerging as a big player in the field of lantibiotic and is responsible for Mutacin 1140 (MU1140), a groundbreaking lantibiotic, and over 700 analogs engineered, manufactured, and tested for safety, toxicity, stability, manufacturability, and drug activity.

Trading at under $3.00 per share and a very well structured share count,  this company remains a tremendous bargain and a huge opportunity for profits at this undervalued level.